Knee injections for obese patients with knee arthritis
Comparison of Varying Doses of Steroid for Intra-articular Knee Injections
PHASE4 · Mayo Clinic · NCT06782529
This study is testing whether low-dose corticosteroid injections can help obese patients with knee arthritis feel better and move easier, just like the standard-dose injections do.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 55 Years to 85 Years |
| Sex | All |
| Sponsor | Mayo Clinic (other) |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT06782529 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of low-dose versus standard-dose corticosteroid injections in obese patients suffering from knee osteoarthritis. It aims to determine whether the low-dose treatment is non-inferior in improving pain and function compared to the standard dose. The study will involve patients with a body mass index (BMI) of 30 kg/m2 or higher who have radiographic evidence of knee osteoarthritis and are seeking steroid injections. Participants will be monitored for changes in knee pain and functional outcomes following treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are obese patients with a BMI of 30 kg/m2 or higher who have been diagnosed with knee osteoarthritis.
Not a fit: Patients with a BMI below 30 kg/m2 or those with uncontrolled diabetes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a safer and equally effective treatment option for obese patients with knee arthritis.
How similar studies have performed: Other studies have shown promising results with corticosteroid injections for knee osteoarthritis, but this specific comparison of low-dose versus standard-dose in obese patients is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Patients with BMI ≥30 kg/m2 and radiograph-proven knee osteoarthritis who are interested in receiving a steroid injection for knee arthritis. Exclusion Criteria: * BMI \< 30 kg/m2 * Uncontrolled diabetics with a hemoglobin A1c \> 8% * No other treatment within the time frame of the study. * Patients that are undergoing physical therapy at the time of the study.
Where this trial is running
Jacksonville, Florida
- Mayo Clinic in Florida — Jacksonville, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: Jeffrey P Nadwodny, DO — Mayo Clinic
- Study coordinator: Jeffrey P Nadwodny, DO
- Email: nadwodny.jeffrey@mayo.edu
- Phone: 904 953 6722
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Osteoarthritis of Knee, Knee Osteoarthritis, Corticosteroid Injection, Obesity